G(M1) Ganglioside

A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis.

Also Known As:

GM1a Monosialoganglioside; Ceramide, Monosialosyl Tetraglycosyl; Ganglioside, GM1; Monosialoganglioside, GM1a; Tetraglycosyl Ceramide, Monosialosyl; GM1 Ganglioside; Monosialosyl Tetraglycosyl Ceramide; Ganglioside GM1

Networked: 444 relevant articles (22 outcomes, 55 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Wu, Gusheng: 9 articles (01/2022 - 09/2002)
2.	Yanagisawa, Katsuhiko: 9 articles (05/2015 - 03/2002)
3.	Ledeen, Robert W: 8 articles (01/2020 - 09/2002)
4.	Schneider, Jay S: 7 articles (01/2022 - 05/2010)
5.	Chiricozzi, Elena: 6 articles (02/2022 - 12/2017)
6.	Sonnino, Sandro: 6 articles (02/2022 - 12/2017)
7.	Lu, Zi-Hua: 6 articles (01/2022 - 04/2009)
8.	Gabius, Hans-Joachim: 6 articles (02/2016 - 03/2005)
9.	Fazzari, Maria: 5 articles (02/2022 - 01/2019)
10.	Lunghi, Giulia: 5 articles (02/2022 - 01/2019)

Related Diseases

1.	Stroke (Strokes) 01/01/1991 - "Is ganglioside GM1 effective in the treatment of stroke?" 01/01/2016 - "Protection against Experimental Stroke by Ganglioside GM1 Is Associated with the Inhibition of Autophagy." 01/01/1991 - "Nine double-blind, placebo-controlled clinical trials involving 784 patients with nonhaemorrhagic stroke have been reviewed to investigate the clinical efficacy of ganglioside GM1 in this disorder. " 05/01/1989 - "Trial of ganglioside GM1 in acute stroke." 09/01/1988 - "Trial of ganglioside GM1 in acute stroke."
2.	Parkinson Disease (Parkinson's Disease) 06/01/1998 - "Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study." 01/01/2015 - "Preclinical and clinical studies have previously shown that systemic administration of GM1 ganglioside has neuroprotective and neurorestorative properties in Parkinson's disease (PD) models and in PD patients. " 01/15/2013 - "The present single center, double-blind, delayed start study was conducted to examine possible symptomatic and disease-modifying effects of GM1 ganglioside in Parkinson's disease (PD). " 01/15/2013 - "A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients." 05/15/2010 - "GM1 ganglioside in Parkinson's disease: Results of a five year open study."
3.	Spinal Cord Injuries (Spinal Cord Injury) 08/01/1994 - "Has GM1 ganglioside been shown to be effective in the restoration of neurologic function in persons with chronic spinal cord injury? " 01/01/1990 - "A prospective, randomized, placebo-controlled, double-blinded spinal cord injury GM1 ganglioside drug trial was completed. " 10/01/1998 - "Taken together, these observations raise a possibility that other pharmacological agents that inhibit neutrophil activation used in conjunction with MPS or GM1 ganglioside may have a synergistic effect in the treatment of traumatic spinal cord injury in humans." 10/01/1996 - "We review the evidence supporting the role of glucocorticosteroids, trilazad, and GM1 ganglioside in spinal cord injury and provide our critique of the published studies, along with our recommendations for pharmacologic therapy for this complex and difficult problem." 08/01/1992 - "Continued investigation of the pathophysiology of primary and secondary neuronal injury following acute spinal cord injury (SCI) has led to positive results in two medical treatment protocols: methylprednisolone and GM1 ganglioside. "
4.	GM1 Gangliosidosis (Gangliosidosis GM1) 12/01/2019 - "GLB1 knockout organoids microinjected with AAV9-GLB1 vector showed a significant increase in β-gal activity and a significant reduction in GM1 ganglioside content compared with AAV9-GFP-injected organoids, demonstrating the efficacy of an AAV9 gene therapy-based approach in GM1 gangliosidosis. " 10/21/2023 - "Our findings highlight NEU3's role in ameliorating the consequences of Glb1 deletion in mice, provide insights into NEU3's differential effects between mice and humans in GM1 gangliosidosis, and offer a potential therapeutic approach for reducing toxic GM1 ganglioside accumulation in GM1 gangliosidosis patients." 08/12/2022 - "Recently, we established a method for measuring and verifying changes in GM1 ganglioside levels in peripheral blood lymphocytes in patients with GM1 gangliosidosis. " 12/01/2019 - "Human GLB1 knockout cerebral organoids: A model system for testing AAV9-mediated GLB1 gene therapy for reducing GM1 ganglioside storage in GM1 gangliosidosis." 11/27/2019 - "We detected a strong correlation between GM1 ganglioside content and the clinical severity of GM1 gangliosidosis. "
5.	Traumatic Brain Injuries (Traumatic Brain Injury) 01/01/2018 - "In the present study, we have found a significant reduction of GM1 ganglioside levels in the cortex in a closed head traumatic brain injury model of a mouse, induced by a weight drop device. " 01/01/2018 - "GM1 ganglioside prevents axonal regeneration inhibition and cognitive deficits in a mouse model of traumatic brain injury." 01/01/2017 - "Restoring GM1 ganglioside expression ameliorates axonal outgrowth inhibition and cognitive impairments induced by blast traumatic brain injury." 02/01/2003 - "To observe the effects of ganglioside GM1 on reduction of brain edema and amelioration of cerebral metabolism after traumatic brain injury (TBI). " 02/01/2003 - "Effects of ganglioside GM1 on reduction of brain edema and amelioration of cerebral metabolism after traumatic brain injury."

Related Drugs and Biologics

1.	Glycosphingolipids
2.	Oligosaccharides
3.	Biomarkers (Surrogate Marker)
4.	Methylprednisolone
5.	Cholinergic Agents (Cholinergics)
6.	Glutamic Acid (Glutamate)
7.	Antipsychotic Agents (Antipsychotics)
8.	Haloperidol (Haldol)
9.	6-hydroxydopa
10.	Gangliosides

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Transplantation
4.	Intramuscular Injections
5.	Hemodilution